DOCSLIB.ORG

Minimizing Time to Plasma Administration and Fresh Frozen Plasma Waste

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Minimizing Time to Plasma Administration and Fresh Frozen Plasma Waste 1.0 QUALITY IMPROVEMENT ANCC Contact Hours 11/23/2020 on 53s0QsWYOnF7r0gOgKxttwWUl05ogzRZsSVjE1+xDug/QiRuHwucAcDdWFN3zl7DXQ+pDjAPxIsGDj7boF+X3TGRNWD5o5VwVzZLuNqA5MOvyFe0/+LaKK0LsG7cwSF7yyaNcewrxzsqvk2cP7OUiAMEZMNh/dbyWUxJAwE6cJ+qQx6/B5443g== by https://journals.lww.com/journaloftraumanursing from Downloaded Downloaded Minimizing Time to Plasma Administration from and Fresh Frozen Plasma Waste: A Multimodal https://journals.lww.com/journaloftraumanursing Approach to Improve Massive Transfusion at a Level 1 Trauma Center ■ ■ Wendy Hyatt , BSN, RN, CEN, TCRN James R. Yon , MD Stephanie Haley-Andrews , BSN, RN by 53s0QsWYOnF7r0gOgKxttwWUl05ogzRZsSVjE1+xDug/QiRuHwucAcDdWFN3zl7DXQ+pDjAPxIsGDj7boF+X3TGRNWD5o5VwVzZLuNqA5MOvyFe0/+LaKK0LsG7cwSF7yyaNcewrxzsqvk2cP7OUiAMEZMNh/dbyWUxJAwE6cJ+qQx6/B5443g== permissive hypotension, and balanced resuscitation ABSTRACT with early plasma, platelets, and red blood cells (RBCs) Massive transfusion protocols are part of damage control (Holcomb et al., 2015). resuscitation for hemorrhaging trauma patients with the The American College of Surgeons (ACS) and the goal of returning the patient to hemodynamic stability. It is Eastern Association for the Surgery of Trauma (EAST) essential that patients receive blood products immediately have established best practice guidelines to direct DCR and in the proper ratios. At our metropolitan Level 1 trauma and MTP for trauma patients experiencing uncontrolled center, we identified several challenges to deploying massive hemorrhage. These guidelines include early and rapid transfusion rapidly and within the recommended ratio deployment of blood products in a ratio of 1:1:1, plas- guidelines. In 2016, we implemented a quality improvement ma to RBCs to platelets ( ACS, 2013 ; Cannon et al., 2017 ). project addressing 4 opportunities: fresh frozen plasma Trauma centers should review the ACS guidelines and (FFP) bag breakage, plasma options, blood bank equipment, compare their current practice with the guidelines, iden- and multidisciplinary policy revision. Implementing tifying areas that need modifications to align with current packaging and shipping improvements, utilization of new recommendations. products, and updating protocols have resulted in a 50% Massive transfusion is a high-risk, low-frequency event decrease in FFP bag breakage rates, a dramatic decrease for most hospitals. Our facility admits more than 2,600 in time for patients receiving massive transfusion to receive trauma patients per year. On average, 25 patients per year plasma products (mean time 3.5 min), and patients being receive MTP. Consistent monitoring of MTP in compari- administered the recommended ratio of blood products. son with MTP guidelines can identify opportunities for improvement. Key Words Hemorrhage , Liquid plasma , Massive transfusion protocol (MTP) , Trauma METHODS One recommendation from the ACS Trauma Quality Im- reventable death after injury is defined as those provement Program (TQIP) massive transfusion guideline casualties whose lives could have been saved by states that universally compatible RBCs and thawed plas- appropriate and timely medical care, irrespective of ma should be immediately available (ACS, 2013). Our fa- tactical, logistical, or environmental issues (Berwick, cility had identified an opportunity for improvement with PDowney, & Cornett, 2016). When evaluating deaths the frequency of bag breakage (and waste) when thawing from traumatic injury, hemorrhagic shock continues fresh frozen plasma (FFP). Our facility was experiencing to be the leading cause of preventable death ( Spinella, bag breakage rates between 10.7% and 14.5%. All bags of 2017 ). Damage control resuscitation (DCR) strategies FFP are visually inspected before being thawed, but there were developed to address uncontrolled hemorrhage. can be tiny holes or tears in the bags that are not visible. These strategies include minimizing crystalloid infusion, The holes occur during the manufacturing, shipping, and processing of the FFP bags before thawing in the facility’s Author Affiliations: UCHealth Highlands Ranch Hospital, Highlands blood bank. These holes are only identified after thawing. Ranch, Colorado; and HealthONE Swedish Medical Center, Englewood, on Two common methods for thawing FFP are the use of a 11/23/2020 Colorado . The authors declare no conflict of interest. water bath thawer and a microwave. Water bath thawers Correspondence: Wendy Hyatt, BSN, RN, CEN, TCRN, UCHealth and microwaves typically take 20 and 10 min, respec- Highlands Ranch Hospital, 1500 Park Central Dr, Highlands Ranch, CO tively, to thaw a bag of FFP. After identifying a bag with a 80129 ( [email protected] ). hole in it, the bag of FFP is unusable and the process of DOI: 10.1097/JTN.0000000000000460 thawing would begin again, creating significant delays in 234 WWW.JOURNALOFTRAUMANURSING.COM Volume 26 | Number 5 | September-October 2019 Copyright © 2019 Society of Trauma Nurses. Unauthorized reproduction of this article is prohibited. delivering plasma to hemorrhaging patients. After identi- mately 30% across all samples. Factor VII and Factor VIII fying a high rate of bag breakage, the blood bank coordi- also decreased significantly ranging from 5% to 22% be- nator contacted two major national blood product suppli- tween all samples. Factor II, Factor X, and Factor XIII ers, Bonfils Blood Center (now Vitalant after acquisition showed minimal changes during storage. Although there and name change) and American Red Cross, to assess is a demonstrated decrease in coagulation factors of liquid and track broken FFP bag rates related to the manufac- plasma over time, it maintains at least 50% of factor activ- turing, packing, and shipping processes. Both organiza- ity and thrombin-generating capacity ( Backholer et al., tions agreed to investigate the issue further. Bonfils Blood 2017 ). Additional research has compared liquid plasma Center identified a trend in the broken FFP bag rates with with thawed plasma to compare two immediately availa- one specific bag type used to hold the FFP. It agreed to ble products. Backholer et al. (2017) found liquid plasma discontinue using the bag with the high failure rate. The to be comparable with thawed plasma in hemostatic vari- American Red Cross identified an increased rate of broken ables. Matijevic et al. (2012) found the hemostatic profile plasma bags when using a specific shipping company. It of liquid plasma to be better and sustained five times formed a nationwide working group to evaluate the ship- longer than thawed plasma. Their research demonstrated ping process for blood products. Through the working that in liquid plasma, most coagulation factors were sta- group, it identified an issue with the packaging materials ble at 26 days of storage and retained at least 88% of used by the shipping company. The American Red Cross the initial activities, which was better in comparison with then changed the packaging materials used to ship its thawed plasma stored at 5 days. They also found liquid product in an attempt to decrease defective products. plasma to have a significant number of residual plate- Plasma is essential for controlling hemorrhage during lets, which contribute to clot strength. The platelets are massive transfusion because it contains proteins for blood destroyed in the freeze–thaw cycle of thawed plasma. In clotting. In the United States, there are seven plasma prod- summary, liquid plasma provides superior shelf life than ucts available, four frozen plasma products and three liq- thawed plasma or FFP ( Van, Holcomb, & Schreiber, 2017 ). uid state products ( American Association of Blood Banks, There are some limitations to utilizing liquid plasma. Cur- 2017 ). Two of the liquid state products are derived from rently, the only indication for liquid plasma is the initial FFP in the form of thawed plasma. The third liquid prod- treatment of patients receiving massive transfusion ( Amer- uct is liquid plasma. Liquid plasma is unique in that it ican Association of Blood Banks, 2017 ). Liquid plasma has is never frozen. It is separated from whole blood and a shelf life of 26 days, which is longer than thawed plasma stored at 1–6 ° C. Liquid plasma provides several benefits with a shelf life of 5 days, but significantly shorter than during massive transfusion. The immediate availability of that of FFP with a shelf life of 365 days when it remains the product eliminates delays in plasma support during frozen. Liquid plasma has been used in Europe since the MTP. Snyder et al. (2009) found in their study regarding 1980s but only recently has become utilized regularly in the delivery of blood products during MTP the medium the United States ( Backholer et al., 2017 ; Gosselin et al., time to the first unit of RBCs was 18 min whereas the 2013 ). Although liquid plasma usage has become more medium time to the first unit of plasma was 93 min. With frequent, it is still not widely used across the country. After the use of liquid plasma, blood products can then be is- reviewing the research and evaluating the risks and ben- sued in correct ratios instead of trying to “catch up” with efits of liquid plasma in our protocol, our multidisciplinary plasma products during the MTP. When utilizing liquid process improvement team chose to implement the use of plasma in the initial phases of MTP, it provides sufficient liquid plasma for the initial phases of massive transfusion. time to thaw additional FFP for continued massive trans- Hospitals can choose to use microwaves
Load more

Recommended publications
  • Transfusion Service Introduction Blood/Blood Products Requests and Turnaround Time Expectations
    Transfusion Service Introduction All blood products and blood components are supplied to UnityPoint Health-Meriter Hospital by the American Red Cross Blood Services. Pathology consultation is available regarding blood and/or components and dosages. ABO and Rho(D)—specific type is used whenever possible for leuko-poor packed cell transfusions. ABO-compatible blood is used for all plasma and platelet components whenever possible. For any orders involving HLA-matched components, the patient must have been HLA typed (sent to the American Red Cross) a minimum of 48 hours prior to intended infusion of the component. HLA typing is only required once. Blood components that are thawed, pooled, washed, volume-reduced, or deglycerolized for a patient will be charged to the patient even if not transfused. The charge is done because these components may not be suitable for another patient. Examples include: Autologous or directed donations Pooled cryoprecipitate 4-hour expiration Thawed fresh frozen plasma 24-hour expiration Thawed cryoprecipitate 6-hour expiration Deglycerolized red cells 24-hour expiration Washed red cells 24-hour expiration All blood components must be completely infused within 4 hours of release from UnityPoint Health-Meriter Laboratories Blood Bank, or be infused within the expiration time. Refer to UnityPoint Health -Meriter’s Blood and Blood Products Transfusion Policy #123 for additional information located on MyMeriter. Blood/Blood Products Requests and Turnaround Time Expectations Requests from UnityPoint Health-Meriter Hospital are entered in the hospital computer system and print in the UnityPoint Health- Meriter Laboratories Blood Bank. For the comfort of the patient, it is important to coordinate collection for other tests with Blood Bank specimens.
    [Show full text]
  • Fresh Frozen Plasma in General Practice
    Practical guide to using frozen and fresh frozen plasma in general practice Why every practice should keep a bag in the freezer Kit Sturgess; MA; VetMB; PhD; CertVR; DSAM; CertVC; FRCVS RCVS Recognised Specialist in Small Animal Medicine Advanced Practitioner in Veterinary Cardiology Introduction Keeping stock at reasonable levels in a practice is vital to good business management balancing the need to have a product available against the costs of keeping stock that is not used and potentially may go out of date and need to be replaced (as well as subtle small costs of space, stock taking, disposal of out-of-date product etc.). Practices need, therefore, to make decisions about preparedness for ‘what if’ scenarios and have protocols in place. The difficult question for many practices is how bizarre/uncommon should these scenarios be to warrant keeping a drug or treatment in stock or buying a specialist piece of equipment. This can only really be answered on an individual practice basis as it will depend on the type of cases seen as well as the likely ability of clients to want to pay if the treatment/investigation is expensive and the relationship with other local practices in terms of borrowing treatments or using equipment. It is also important to try and understand the value that a particular drug or treatment will have on morbidity and mortality of a particular condition and whether the patient could be referred onwards if necessary so not having calcium available if presented with a seizuring hypocalcaemic patient would be a significant issue in that patient’s care.
    [Show full text]
  • Blood Banking/Transfusion Medicine Fellowship Program
    DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE BLOOD BANKING/TRANSFUSION MEDICINE FELLOWSHIP PROGRAM THIS NEW ONE-YEAR ACGME-ACCREDITED FELLOWSHIP IN BLOOD BANKING/TRANSFUSION MEDICINE OFFERS STATE OF THE ART COMPREHENSIVE TRAINING IN BLOOD BANKING, COAGULATION, APHERESIS, AND HEMOTHERAPY AT THE MEMORIAL HERMANN HOSPITAL (MHH)-TEXAS MEDICAL CENTER (TMC) FOR PEDIATRICS AND ADULTS. This clinically-oriented fellowship is ideal for the candidate looking for exceptional experience in hemotherapy decision-making and coagulation consultation. We have a full spectrum of medical and surgical specialties, including a level 1 trauma center, as well as a busy solid organ transplant service (renal, liver, pancreas, cardiac, and lung). Fellows will rotate through: Our unique hemotherapy service: This innovative clinical consultative service for the Heart and Vascular Institute (HVI) allows fellows to serve as interventional blood banking consultants at the bed side as part of a multidisciplinary care team; our patients have complex bleeding and coagulopathy issues. Therapeutic apheresis service: This consultative service provide 24/7 direct patient care covering therapeutic plasmapheresis, red blood cell (RBC) exchanges, photopheresis, plateletpheresis, leukoreduction, therapeutic phlebotomies, and other related procedures on an inpatient and outpatient basis. We performed approximately over 1000 therapeutic plasma exchanges and RBC exchanges every year. Bloodbank: The MHH-TMC reference lab is one of the largest in Southeast Texas. This rotation provides extensive experience in interpreting antibody panel reports, working up transfusion reactions, investigating blood compatibility/incompatibility issues, and monitoring component usage. Gulf Coast Regional Blood Center: This rotation provides donor exposure in one of the largest community blood donation centers in the US as well as cellular therapy and immunohematology training.
    [Show full text]
  • Transfusion Medicine/Blood Banking
    Transfusion Medicine/Blood Banking REQUIRED rotation This is a onetime rotation and is not planned by PGY level. Objective: The objective of this rotation is to teach fellows the clinical and laboratory aspects of Transfusion Medicine and Blood Banking as it impacts hematology/oncology. Goals: The goal of this rotation is to teach fellows blood ordering practices, the difference of type and screen and type and cross matches and selection of appropriate products for transfusion. Fellows will also learn to perform, watch type and screen red cell antibodies and will learn the significance of ABO, Rh and other blood group antigen systems briefly so as to understand the significance of red cell antibodies in transfusion practices. Fellows will learn the different types of Blood components, their indications and contraindications and component modification. e.g. Irradiated and washed products, and special product request and transfusions e.g. granulocyte transfusion, CMV negative products etc. Fellows will learn and become proficient in the laboratory aspects of autoimmune hemolytic anemia, coagulopathies and bleeding disorders in relation to massive transfusions and the laboratory aspects and management of platelet refractoriness. Fellows will learn some aspects of coagulation factor replacement for factor deficiencies and inhibitors. Activities: Fellows will rotate in the Blood Bank at UMC and learn to perform, observe and interpret standard blood bank procedures such as ABO Rh typing, Antibody Screen, Antibody Identification and Direct Antiglobulin Test (DAT). Fellows will also watch platelet cross matching for platelet refractoriness. Fellows will attend and present a few didactic lectures of about 40 minutes on Blood Bank related topics as they apply to hematology/oncology like blood group antigens, Blood Component therapy, Transfusion reactions, Autoimmune hemolytic anemia, Platelet immunology and HLA as it applies to transfusion medicine.
    [Show full text]
  • Donor Sex, Age and Ethnicity Impact Stored Red Blood Cell Antioxidant Metabolism Through Mechanisms in Part Explained by Glucose
    Blood Transfusion SUPPLEMENTARY APPENDIX Donor sex, age and ethnicity impact stored red blood cell antioxidant metabolism through mechanisms in part explained by glucose 6-phosphate dehydrogenase levels and activity Angelo D’Alessandro, 1,2,3 Xiaoyun Fu, 4 Tamir Kanias, 3,5 Julie A. Reisz, 1 Rachel Culp-Hill, 1 Yuelong Guo, 6 Mark T. Gladwin, 5 Grier Page, 6 Steve Kleinman, 7 Marion Lanteri, 8 Mars Stone, 8 Michael P. Busch, 8# and James C. Zimring 9# for the Recipi - ent Epidemiology and Donor Evaluation Study-III (REDS III) 1Department of Biochemistry and Molecular Genetics, University of Colorado Denver – Anschutz Medical Campus, Aurora, CO, USA; 2De - partment of Medicine – Division of Hematology, University of Colorado Denver – Anschutz Medical Campus, Aurora, CO, USA; 3Vitalant Re - search Institute (previously Blood Systems Research Institute), Denver, CO, USA; 4Bloodworks Northwest Research Institute, Seattle, WA, USA; 5University of Pittsburgh, Pittsburgh, PA, USA; 6RTI International, Atlanta, GA, USA; 7University of British Columbia, Victoria, Canada; 8Vi - talant Research Institute (previously Blood Systems Research Institute), San Francisco, CA, USA and 9University of Virginia, Charlotesville, VA, USA #MPB and JCZ contributed equally as co-senior authors ©2021 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2020.246603 Received: January 7, 2020. Accepted: March 27, 2020. Pre-published: April 2, 2020. Correspondence: ANGELO D’ALESSANDRO - [email protected] SUPPLEMENTARY MATERIAL
    [Show full text]
  • Blood Establishment Registration and Product Listing .3 Change in Information
    FORM APPROVED: OMB No. 0910-0052. Expiration Date: March 31, 2015. See page 3 for Burden Statement. 1. REGISTRATION NUMBER 3. REASON FOR SUBMISSION FOR FDA USE ONLY DEPARTMENT OF HEALTH AND HUMAN SERVICES FEI : .1 ANNUAL REGISTRATION FOOD AND DRUG ADMINISTRATION CFN : .2 INITIAL REGISTRATION 2. U.S. LICENSE NUMBER BLOOD ESTABLISHMENT REGISTRATION AND PRODUCT LISTING .3 CHANGE IN INFORMATION PLEASE READ INSTRUCTIONS CAREFULLY. Be sure to indicate any changes in your legal This form is authorized by Sections 510(b), (j) and 704 of the Federal Food, Drug, and Cosmetic Act (Title name or actual location in item 4, and any changes in your mailing address in item 6. Print all 21, United States Code 360(b), (j) and 374). Failure to report this information is a violation of Section 301(f) entries and make all corrections in red ink, if possible. Enter your phone number in item 8.3 and and (p) of the Act (Title 21, United States Code 331(f) and (p)) and can result in a fine of up to $1,000 or the phone number of your actual location in item 4.1. Sign the form and return to FDA. After imprisonment up to one year or both, pursuant to Section 303(a) of the Act (Title 21, United States Code validation, you will receive your Official Registration for the ensuing year. 33.3(a)). DISTRICT OFFICE: ENTER ALL CHANGES IN RED INK AND CIRCLE. 9. TYPE OF OWNERSHIP 10. TYPE ESTABLISHMENT (Check all boxes that describe routine or autologous operations.) 4. LEGAL NAME AND LOCATION (Include legal name, number and street, city, .1 SINGLE PROPRIETORSHIP .1 COMMUNITY (NON-HOSPITAL) BLOOD BANK state, country, and post office code.) .2 PARTNERSHIP .2 HOSPITAL BLOOD BANK .3 CORPORATION profit ___ non-profit ___ .3 PLASMAPHERESIS CENTER .4 COOPERATIVE ASSOCIATION .4 PRODUCT TESTING LABORATORY .5 FEDERAL (non-military) a.
    [Show full text]
  • Cryoprecipitate
    VUMC Blood Bank Website Products Page Cryoprecipitate Dosage: The VUMC blood bank maintains two distinct cryoprecipitate products. Adult patients will receive pre-pooled units of cryoprecipitate, these units contain 5 individual cryo units. Providers caring for adult patients can order pre-pooled cryoprecipitate in increments, with a traditional order of 2 pre-pooled cryoprecipitate units for an adult patient. Pediatric patients at VUMC receive cryoprecipitate via individual units according to weight based transfusion guidelines (recommended 10-15 mL/kg). Orders for cryoprecipitate that deviate from this algorithm - as well as orders for cryoprecipitate for patients without a recent fibrinogen level document in Starpanel - are flagged for review by the blood bank resident and/or the medical director. Introduction: According to standards set by the AABB, each unit of cryoprecipitate must contain at least 150 mg of fibrinogen. Cryoprecipitate also contains at least 80 IU of Factor VIII and appreciable amounts of von Willebrand Factor (vWF) and Factor XIII. Cryoprecipitate does not contain appreciable amounts of the other clotting factors. Indications: The most common indication for cryoprecipitate transfusion is hypofibrinogenemia, usually in the setting of DIC or major surgery but occasionally do to hereditary hypofibrinogenemia. Less commonly, cryoprecipitate has been used to provide factor replacement in Factor XIII deficiency. Please note, that human factor XIII concentrates are FDA approved for maintenance therapy (www.corifact.com). Cryoprecipitate should NOT be used for treatment of hemophilia A (Factor VIII deficiency) or von Willebrand’s disease. Vanderbilt discourages the use of cryoprecipitate as a post-surgical fibrin sealant. Special Information Unlike RBCs, platelets, and FFP, once cryoprecipitate is thawed, it cannot be re-stocked (re-frozen) by the blood bank.
    [Show full text]
  • Red Blood Cell Transfusions –
    Peer Reviewed VETcpd - Internal Medicine Jenny Walton BVM&S MRCVS Jenny qualified from R(D)SVS in Red blood cell transfusions – 1998 - she worked in mixed practice when, what and how to do it! for 4 years before moving into the Red cell transfusions are now a relatively common intervention in veterinary practice field of small in the UK and help in the treatment of many patients. This is largely due to the animal emergency availability of blood products, such as Packed Red Blood Cells (PRBC) , from blood and critical care banks supplying directly to practices. After donation, red cells are separated from with Vets Now for 12 years. Through plasma into a concentrated packed cell form, a nutrient extender is then added to Vets Now, she ran the practical trial them. This allows the red cells to be stored for up to 42 days before being transfused researching canine blood banking in 2005-2006 – launching Pet Blood Bank into patients. DEA 1 blood typing prior to transfusion is essential and cross matching UK (PBB) alongside Wendy Barnett should be performed for second transfusions. Blood products are administered in 2007. She acts as the Veterinary through a filtered giving set and patients monitored closely for transfusion reactions. Supervisor for PBB, her role includes Transfusion reactions are thankfully rare but potentially life threatening. advising practitioners daily on the appropriate use of PBB blood products, Key words: Canine, Packed Red Blood Cells (PRBC), transfusion, blood typing, overseeing the practical and VMD cross matching, transfusion reactions legislative veterinary aspects of blood collection at PBB and leading research on future development opportunities.
    [Show full text]
  • A Patient's Guide to Blood Transfusions
    References: This brochure is provided as a source of information and is not • Circular of Information for the considered a replacement for the Use of Human Blood and Blood Informed Consent process prior to A Patient’s Components. AABB. Nov 2013 the transfusion of blood. (revised April 2014) Guide to Blood • AABB Technical Manual. 18th Edition. Transfusion Distributed by the This brochure was developed Medical Board of California by the California Department of Health Services, Laboratory Field To place an order for this brochure, Services (850 Marina Bay Parkway, please FAX your request to: California Richmond, CA 94804) (916) 263-2479 Department of Health Services In partnership with the Medical This information may be obtained Technical Advisory Committee of the electronically at: June 2016 Blood Centers of California. http://www.mbc.ca.gov/ For information about brochure Publications/Brochures/Blood_ contents, please call Transfusions.aspx Laboratory Field Services 213 620-6574. Revised 06/2016 This document provides written Other rare but more serious complications • Medications (certain medications may information regarding the benefits, risks, include severe allergic reactions, heart increase blood volume prior to surgery and alternatives of transfusion of blood failure due to fluid overload, acute or reduce active bleeding to lessen the products (including red blood cells, pulmonary edema (fluid leaking into the need for transfusion) plasma, platelets, or others) collected from lungs), hemolysis (destruction of red blood the patient (autologous) or another person. cells), shock, or death. These options may be available only if This material serves as a supplement your health, time, and procedure permit. to the discussion you have with your Transfusion of blood products carries a They may not be available at all locations physician.
    [Show full text]
  • Blood Banking (Transfusion Services)
    Blood Banking (Transfusion Service)—Blood Transfusion Policies and Standard Practices Kalispell Regional Medical Center maintains a transfusion service providing blood and blood products for routine and emergency situations. A pathologist is available for consultation at all times. Pretransfusion Testing Prior to the issuance of blood, the patient’s ABO group and Rh type must be determined, and an antibody screen and crossmatch must be performed. Prior to the issuance of blood products which lack red blood cells (eg, fresh frozen plasma), only the ABO group and Rh type need to be determined. There are 3 types of requests for pretransfusion testing: 1. CLOT “Clot to Hold, Blood” is ordered when blood products are not anticipated but may become necessary. The specimen is drawn and labeled for potential transfusion; however, no testing is performed. Should blood products be required, allow a minimum of 1 hour for availability. 2. TS “Type and Screen, Blood” consists of an ABO group, Rh type, and antibody screen and can be ordered when the need for crossmatched products is unlikely, but may be required in an unexpected situation. In most cases, an abbreviated crossmatch can be completed within 15 minutes. If the patient has a clinically significant antibody, 2 units of blood will be made available for that patient. 3. PC “Type and Crossmatch” consists of ABO group, Rh type, antibody screen, and crossmatch. This is ordered when crossmatched products must be available immediately. All blood products containing RBCs must be crossmatched (including autologous and directed donor RBCs). Allow a minimum of 1 hour for availability.
    [Show full text]
  • Screening Donated Blood for Transfusion- Transmissible Infections
    Screening Donated Blood for Transfusion- Transmissible Infections Recommendations Screening Donated Blood for Transfusion- Transmissible Infections Recommendations WHO Library Cataloguing-in-Publication Data Screening donated blood for transfusion-transmissible infections: recommendations. 1.Blood transfusion - adverse effects. 2.Blood transfusion - standards. 3.Disease transmission, Infectious - prevention and control. 4.Donor selection. 5.National health programs. I.World Health Organization. ISBN 978 92 4 154788 8 (NLM classification: WB 356) Development of this publication was supported by Cooperative Agreement No. U62/PS024044-05 from the Department of Health and Human Services/Centers for Disease Control and Prevention (CDC), National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Global AIDS Program (GAP), United States of America. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC. © World Health Organization 2010 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • Clinical Transfusion Practice
    Clinical Transfusion Practice Guidelines for Medical Interns Foreword Blood transfusion is an important part of day‐to‐day clinical practice. Blood and blood products provide unique and life‐saving therapeutic benefits to patients. However, due to resource constraints, it is not always possible for the blood product to reach the patient at the right time. The major concern from the point of view of both user (recipient) and prescriber (clinician) is for safe, effective and quality blood to be available when required. Standard practices should be in place to include appropriate testing, careful selection of donors, screening of donations, compatibility testing, storage of donations for clinical use, issue of blood units for either routine or emergency use, appropriate use of blood supplied or the return of units not needed after issue, and reports of transfusion reactions – all are major aspects where standard practices need to be implemented. In order to implement guidelines for standard transfusion practices, a coordinated team effort by clinicians, blood transfusion experts, other laboratory personnel and health care providers involved in the transfusion chain, is needed. Orientation of standard practices is vital in addressing these issues to improve the quality of blood transfusion services. Bedside clinicians and medical interns are in the forefront of patient management. They are responsible for completing blood request forms, administering blood, monitoring transfusions and being vigilant for the signs and symptoms of adverse reactions.
    [Show full text]